ETST Revenue Plunges 99.9% to $1,000 Amidst Pharmaceutical Sales Halt

TL;DR

ETST is effectively dead in the water with revenue collapsing to $1,000; SELL immediately.

AI Summary

Earth Science Tech, Inc. (ETST) reported a significant decline in revenue for the fiscal year ended March 31, 2025, with total revenue plummeting to $1,000 from $1,000,000 in the prior year, representing a 99.9% decrease. This drastic reduction was primarily driven by a collapse in sales of Pharmaceutical Products (Rx Compound) from $900,000 to $0 and Pharmaceutical Products (Peaks) from $100,000 to $0. The company also reported a net loss, though specific net income figures were not provided in the excerpt. Key business changes include the cessation of sales for its primary pharmaceutical product lines. Major risks include extreme customer concentration, with Customer One, Customer Two, and Customer Three each contributing 0% of revenue in the current fiscal year, down from significant percentages previously. The strategic outlook appears highly uncertain given the near-total loss of revenue and the absence of new product introductions or market expansion plans in the provided data. The company's financial health is severely compromised by this revenue collapse.

Why It Matters

This catastrophic revenue decline to just $1,000 signals a near-complete operational shutdown for Earth Science Tech, Inc., making it a critical red flag for investors. Employees face severe job insecurity as the company's ability to sustain operations is highly questionable. Customers who relied on ETST's pharmaceutical products will need to find alternative suppliers, potentially impacting patient care. In the broader pharmaceutical market, this highlights the extreme volatility and competitive pressures faced by smaller players, especially those with concentrated product lines, and could lead to market share shifts towards more stable competitors.

Risk Assessment

Risk Level: high — The risk level is high due to the catastrophic 99.9% revenue decline from $1,000,000 to $1,000 for the fiscal year ended March 31, 2025. This indicates a near-total cessation of business operations and an inability to generate meaningful income, posing an existential threat to the company.

Analyst Insight

Investors should divest any holdings in ETST immediately, as the company's financial performance indicates a severe operational failure and an unsustainable business model. This information suggests a high probability of further value erosion and potential delisting.

Financial Highlights

debt To Equity

N/A

revenue

$1,000

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

-99.9%

Revenue Breakdown

Key Numbers

• $1,000 — Total Revenue (Total revenue for fiscal year ended March 31, 2025, down from $1,000,000.)
• $1,000,000 — Prior Year Total Revenue (Total revenue for fiscal year ended March 31, 2024.)
• 99.9% — Revenue Decrease Percentage (Percentage decrease in total revenue from 2024 to 2025.)
• $900,000 — Pharmaceutical Products (Rx Compound) Revenue (2024) (Revenue from Rx Compound products in fiscal year 2024, which dropped to $0 in 2025.)
• $100,000 — Pharmaceutical Products (Peaks) Revenue (2024) (Revenue from Peaks products in fiscal year 2024, which dropped to $0 in 2025.)
• 0% — Customer Concentration (2025) (Revenue contribution from Customer One, Customer Two, and Customer Three in fiscal year 2025.)

Key Players & Entities

• Earth Science Tech, Inc. (company) — filer of the 10-K
• Customer One (company) — former significant customer, now 0% of revenue
• Customer Two (company) — former significant customer, now 0% of revenue
• Customer Three (company) — former significant customer, now 0% of revenue
• 03 Life Sciences (company) — organization name associated with the filer
• Ultimate Novelty Sports Inc. (company) — former company name of ETST

FAQ

Risk Factors

• Near-Total Revenue Collapse [high — financial]: Total revenue for the fiscal year ended March 31, 2025, plummeted to $1,000 from $1,000,000 in the prior year, a 99.9% decrease. This was driven by the complete cessation of sales for key pharmaceutical product lines, Rx Compound and Peaks.
• Extreme Customer Concentration Loss [high — financial]: The company experienced a complete loss of revenue from its previously significant customers: Customer One, Customer Two, and Customer Three, each contributing 0% of revenue in fiscal year 2025. This indicates a critical dependency and failure to retain key business relationships.
• Cessation of Primary Product Sales [high — operational]: Earth Science Tech, Inc. ceased sales of its primary pharmaceutical product lines, Rx Compound and Peaks. This action directly led to the drastic revenue decline and raises questions about the company's future product strategy and operational viability.

Industry Context

Earth Science Tech, Inc. operates within the Pharmaceutical Preparations (SIC 2834) industry. This sector is typically characterized by high R&D investment, stringent regulatory oversight, and competitive market dynamics. Companies often rely on patented products and strong distribution channels for revenue generation.

Regulatory Implications

The cessation of sales for pharmaceutical products could trigger regulatory scrutiny regarding product lifecycle management and compliance with any prior market authorizations. Failure to maintain product lines may also impact future regulatory standing.

What Investors Should Do

1. Seek clarification on future business strategy.
2. Investigate the reasons for customer loss.
3. Assess the company's cash burn rate and runway.

Key Dates

• 2025-03-31: Fiscal Year End — Marks the end of the reporting period during which revenue collapsed by 99.9% and primary product sales ceased.
• 2024-03-31: Prior Fiscal Year End — Represents the baseline period with $1,000,000 in total revenue, prior to the significant decline.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC) that gives a comprehensive summary of a company's financial performance. (This document provides the detailed financial and operational information for Earth Science Tech, Inc.)

SIC Code 2834

Standard Industrial Classification code for Pharmaceutical Preparations. (Indicates the company's primary industry focus, which is now severely underperforming.)

Fiscal Year End

The last day of a company's accounting period. (Crucial for understanding the time frame of the reported financial results, particularly the drastic revenue drop by March 31, 2025.)

Year-Over-Year Comparison

Compared to the prior fiscal year, Earth Science Tech, Inc. has experienced a catastrophic 99.9% decline in total revenue, falling from $1,000,000 to $1,000. This dramatic decrease is directly attributable to the complete cessation of sales for its Pharmaceutical Products (Rx Compound) and Pharmaceutical Products (Peaks) lines. Consequently, the company has lost all revenue from its previously significant customers (Customer One, Two, and Three), highlighting a severe operational and financial downturn.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on June 27, 2025 regarding Earth Science Tech, Inc. (ETST).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR